Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. ETF
  3. XENE
XENE logo

XENE

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewTechnicalNews
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

XENE News

Xenon Pharmaceuticals CMO Sells Shares Amid RSU Vesting

3d agoFool

Driehaus Capital Increases Stake in Xenon Pharmaceuticals

Mar 13 2026Fool

Xenon Pharmaceuticals Prices $650 Million Upsized Public Offering

Mar 11 2026NASDAQ.COM

Xenon Pharmaceuticals Upsizes Public Offering to $650 Million

Mar 11 2026seekingalpha

Wall Street Analysts Adjust Ratings

Mar 10 2026Benzinga

Xenon Pharmaceuticals Stock Surpasses Analyst Target Price

Mar 10 2026NASDAQ.COM

Xenon Plans New Drug Application Submission

Mar 10 2026stocktwits

Xenon and Relmada Surge on Positive Drug Data

Mar 09 2026Yahoo Finance

Xenon Pharmaceuticals Launches $500 Million Public Offering

Mar 09 2026seekingalpha

Xenon Pharmaceuticals Reports Positive Phase 3 X-TOLE2 Study Results

Mar 09 2026seekingalpha

U.S. Stocks Close Sharply Lower Amid Mixed Trading

Mar 09 2026Benzinga

Oil Price Surge Drives Significant Stock Movements

Mar 09 2026CNBC

Biohaven Shares Fluctuate Following Positive Study Data

Mar 09 2026Benzinga

Relmada Therapeutics Shares Surge 40.8% on Promising Trial Data

Mar 09 2026Benzinga

Xenon Pharmaceuticals Reports Positive Phase 3 X-TOLE2 Study Results

Mar 09 2026Benzinga

U.S. Stocks Drop Over 1% in Morning Trading

Mar 09 2026Benzinga